News >

Nivolumab/Ipilimumab Doubles Intracranial Response in Melanoma Brain Mets

Jason Harris
Published: Thursday, Apr 05, 2018

Georgina V. Long, BSc, PhD, MBBS
Georgina V. Long, BSc, PhD, MBBS
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced an intracranial response of 46% in melanoma patients with asymptomatic, untreated brain metastases. The intracranial response rate (ICR) with nivolumab monotherapy was 20%.

There were no deaths attributed to the study treatment. Nine (26%) patients in cohort A, one (4%) in cohort B, and 1 (6%) in cohort C discontinued study treatment due to AEs.
Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicenter randomised phase 2 study [published online March 27, 2018]. Lancet Oncol. doi: 10.1016/ S1470-2045(18)30139-6.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication